Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CDER, CBER Post FY 2023 Employee Gains, But Behind User Fee Hiring Goals

Executive Summary

US FDA’s drug center reported a net increase of more than 300 employees in FY 2023, while the biologics center saw an overall increase of more than 30.

You may also be interested in...



Congress Gives US FDA Austere Budget But Seeks Boosts On Inspections, IT, And ALS Activities

The minor cut would be masked by user fee revenue increases, but still would be the first time in at least a decade that agency's budget authority has dropped.

US FDA’s Marks Worries Someone May Stop Hybrid Work System

CBER Director Peter Marks said the FDA’s remote and in-person work system is functioning well and continues to help recruitment.

BsUFA III Expands Biosimilar Supplement Review Goals To Speed Approvals

Six supplement categories based on submission content will be created with review goals between three and 10 months.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS149828

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel